SPPI News and Press, Spectrum Pharmaceuticals Inc. From 06/02/22

Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced that management will participate in two upcoming investor conferences: A fireside chat presentation at the Jefferies Healthcare Conference in Ne...

Reduced circulating tumor DNA (ctDNA) and circulating free DNA (cfDNA) levels were associated with tumor shrinkage in patients that responded to poziotinib treatment Poziotinib has received Fast Track designation from FDA and a Prescription Drug User Fee Act (PDUFA) date o...

Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced that management will participate in the upcoming H.C. Wainwright Global Investment Conference, to be held virtually and in Miami Beach from May 23-26,...

Image source: The Motley Fool. Spectrum Pharmaceuticals (NASDAQ: SPPI) Q1 2022 Earnings Call May 12, 2022 , 4:30 p.m. ET Operator Continue reading For further details see: Spectrum Pharmaceuticals (SPPI) Q1 2022 Earnings Call Transcript ...

Spectrum Pharmaceuticals, Inc. (SPPI) Q1 2022 Results Conference Call May 12, 2022 04:30 PM ET Company Participants Michael Grabow - Senior Vice President of Corporate Strategy and Operations Thomas Riga - President and CEO Francois Lebel - Chief Medical Officer Conference Call Participants M...

Spectrum Pharmaceuticals press release (NASDAQ:SPPI): Q1 Non-GAAP EPS of -$0.06. In January, the company received a $20 million strategic equity investment from Hanmi Pharmaceutical. Together with this strategic investment, Spectrum ended the quarter with cash, cash equivalents, and marketabl...

Resubmitted eflapegrastim BLA accepted for review by the FDA, PDUFA date September 9, 2022 Poziotinib NDA under review by FDA with PDUFA date of November 24, 2022 and will be discussed at ODAC meeting in September Positive poziotinib results in treatment naïve pat...

Spectrum Pharmaceuticals (NASDAQ:SPPI) appointed Nora Brennan as CFO, effective May 25, 2022. He has served on the company board and as Chairperson of the Audit Committee since December 2020. Most recently, Ms. Brennan served as CFO of Fore Biotherapeutics, a private ...

Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced the appointment of Nora Brennan as Chief Financial Officer effective May 25, 2022. Ms. Brennan has served on Spectrum’s Board of Directors and ...

Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced it will host a conference call to discuss the first quarter 2022 financial results and provide a corporate update on Thursday, May 12, 2022 at 4:30 p....